Antiviral therapy for pregnant women and children with chronic HBV infection
10.3969/j.issn.1001-5256.2022.11.003
- VernacularTitle:慢性HBV感染孕妇和儿童的抗病毒治疗药物选择及疗效评价
- Author:
Aoxue CUI
1
;
Xiaoguang DOU
1
;
Yang DING
1
Author Information
1. Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang 110022, China
- Publication Type:Discussions by Experts
- Keywords:
Hepatitis B Virus;
Pregnant Women;
Child;
Antiviral Agents
- From:
Journal of Clinical Hepatology
2022;38(11):2448-2451
- CountryChina
- Language:Chinese
-
Abstract:
The most important measure for preventing mother-to-child transmission of HBV and reducing chronic HBV infection in children is enhancing the standardized management of chronic HBV infection in pregnant women and their infants. Pregnant women and children are special populations, and antiviral therapy for pregnant women and children with chronic HBV infection differs from that of general population in terms of drug selection and efficacy evaluation. This article will review the selection and efficacy of antiviral drugs for pregnant women and children with chronic HBV infection, in order to help clinicians manage and treat this special population more effectively.
